肝硬化的逆转:从静态终末期到动态可干预状态
综述指出肝硬化全球患病率与死亡率持续上升,1990年以来病例增加超过50%。肝硬化被视为动态可修饰状态,持续病因控制可诱导结构重塑,但逆转不等于完全恢复稳态,残留血管功能障碍与肿瘤风险常持续存在。
要点
- 肝硬化是动态可修饰状态,持续病因控制可诱导结构重塑。
- 逆转取决于瘢痕生物学状态与微环境,而非仅纤维化分期。
- 结构改善有预后获益,但不等于完全恢复组织稳态。
核心结论
- 肝硬化不再被视为固定终末期,而是动态可修饰疾病状态,持续病因控制可诱导有意义的架构重塑。
- 可逆性由瘢痕的生物学状态及其微环境决定,而非单纯纤维化分期。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 1990年以来全球肝硬化病例增加超过50%,患病率与死亡率持续上升。
- 单细胞与空间分析显示肝硬化是异质性纤维化微环境,由情境特异性纤维化、免疫和血管细胞表型塑造。
- 近期抗纤维化试验结果令人失望,尤其在MASH相关肝硬化中,提示晚期疾病的结构韧性与传统组织学终点的敏感性有限。
- 结构改善似乎带来可测量的预后获益,但逆转不等于完全恢复组织稳态,残留血管功能障碍与致癌风险常持续存在。
临床怎么用
- 临床应重视持续病因控制以诱导肝硬化结构重塑。
- 评估逆转时需关注瘢痕生物学状态与微环境,而非仅依赖纤维化分期。
- 即使结构改善,仍需监测残留血管功能障碍与肿瘤风险。
局限性
- 近期抗纤维化试验结果令人失望,尤其MASH相关肝硬化,提示传统组织学终点敏感性有限。
- 逆转不等于完全恢复组织稳态,残留血管功能障碍与致癌风险常持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cirrhosis prevalence and mortality continue to rise globally, with a >50% increase in cases since 1990, imposing a growing burden through chronic healthcare needs, recurrent hospitalisation, and liver transplantation, which remains the only definitive cure for advanced disease. Long regarded as a fixed end-stage, cirrhosis is now recognised as a dynamic and modifiable disease state. Sustained aetiological control can induce meaningful architectural remodelling, and single-cell and spatial analyses show that cirrhosis is a heterogeneous fibrotic niche shaped by context-specific fibrogenic, immune, and vascular cell phenotypes. Thus, reversibility is determined not simply by fibrosis stage, but by the biological state of the scar and its microenvironment. Nevertheless, recent disappointing antifibrotic trials, particularly in MASH-related cirrhosis, highlight the structural resilience of advanced disease and the limited sensitivity of conventional histological endpoints. Moreover, although structural improvement appears to confer measurable prognostic benefit, regression does not equate to complete restoration of tissue homeostasis, and residual vascular dysfunction and oncogenic risk often persist. Translating emerging mechanistic insights into precise measurement tools and effective therapies for cirrhosis regression now represents a central challenge in hepatology.
引用
- Fallowfield JA, Ramachandran P, Kendall TJ, et al. Regression of liver cirrhosis. J Hepatol. 2026. PMID: 42342081. doi:10.1016/j.jhep.2026.05.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。